X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Amubarvimab and Romlusevimab are non-competing SARS-CoV-2 monoclonal neutralizing antibodies derived from convalesced COVID-19 patients developed in collaboration with the 3rd People’s Hospital of Shenzhen and Tsinghua University.
Lead Product(s): Amubarvimab,Romlusevimab
Therapeutic Area: Infections and Infectious Diseases Product Name: BRII-196/BRII-198
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: TSB Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 19, 2022
Details:
Everest’s licensing partner Providence is currently evaluating PTX-COVID19-B in a head-to-head clinical trial against Pfizer-BioNTech’s Comirnaty COVID-19 vaccine. Everest and Providence also plan to initiate a trial in 2022 to further expand the indication of PTX-COVID19-B.
Lead Product(s): PTX-COVID19-B
Therapeutic Area: Infections and Infectious Diseases Product Name: PTX-COVID19-B
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Everest Medicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 07, 2022
Details:
Ligand has preclinical data showing its oral BEPro-enabled COVID-19 antivirals to have a favorable blood concentration profile and generate lower levels of active nucleotide in the kidney, a potential site for toxicity, than other oral and intravenous comparators.
Lead Product(s): BEPro-enabled COVID-19 antiviral
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Ligand Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 21, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
